Lectin-conjugated Ellagitannin의 흑색종에 대한 항암활성

• 영문명: Effects of Lectin-conjugated Ellagitannin on Antitumor Activity
• 발행기관: 대한약학회
• 저자명: 김형근(Hyoung Kun Kim) 한기숙(Ki Sook Han) 이도익(Do Ik Lee)
• 간행물 정보: 『약학회지』제44권 제6호 (2000년), 607~612쪽, 전체 6쪽
• 주제분류: 의약학 > 기타의약학
• 파일형태: PDF
• 발행일자: 2000.12.30

영문 초록

Generally, antitumor drugs have strong toxicity and result in damage in normal cells. Previously, lectin has been reported as a tumor cell specific binding protein and tannin as an antitumor substance. In this study, we investgated antitumor activity of lectin-conjugated ellagitannin and used praecoxin A as an ellagitannin source. We injected mouse melanoma cell, B16-F1O, on right the femoral region of C57BL/6 mouse. After 10 hours later, first treatment with praecoxin A, lectin-praecoxin A mixiture and lectin-conjugated praecoxin A was carried and followed by injection I.m. every 48 hours. Praecoxin A extended the life of mice up to 14.8% in comparison with the negative control group at 5mg/kg dose. The life extending ratio of Lectin-praecoxin A mixture was 26.1% at 5mg/kg dose, and the life extending ratio of lectin-conjugated praecoxin A was 28.7% at 5mg/kg dose. On the basis of these findings, we suggest that antitumor activities of lectin-praecoxin A mixiture and lectin-conjugated praecoxin A on survival are better than that of praecoxin A.

키워드

Lectin-conjugated Ellagitannin praecoxin A antitumor activity.